200 related articles for article (PubMed ID: 35429927)
1. Comparing Measurement Properties of the English EQ-5D-Y 3-Level Version With the 5-Level Version in South Africa.
Verstraete J; Amien R; Scott D
Value Health Reg Issues; 2022 Jul; 30():140-147. PubMed ID: 35429927
[TBL] [Abstract][Full Text] [Related]
2. Measurement properties and responsiveness of the EQ-5D-Y-5L compared to the EQ-5D-Y-3L in children and adolescents receiving acute orthopaedic care.
Verstraete J; Marthinus Z; Dix-Peek S; Scott D
Health Qual Life Outcomes; 2022 Feb; 20(1):28. PubMed ID: 35177084
[TBL] [Abstract][Full Text] [Related]
3. Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis.
Lin J; Wong CKH; Cheung JPY; Cheung PWH; Luo N
Eur J Health Econ; 2022 Nov; 23(8):1383-1395. PubMed ID: 35122171
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Psychometric Properties of the EQ-5D-3L-Y and EQ-5D-5L-Y Instruments in Spanish Children and Adolescents.
Pérez-Sousa MÁ; Olivares PR; Ramírez-Vélez R; Gusi N
Value Health; 2021 Dec; 24(12):1799-1806. PubMed ID: 34838278
[TBL] [Abstract][Full Text] [Related]
5. Psychometric performance of the Chichewa versions of the EQ-5D-Y-3L and EQ-5D-Y-5L among healthy and sick children and adolescents in Malawi.
Ngwira LG; Maheswaran H; Verstraete J; Petrou S; Niessen L; Smith SC
J Patient Rep Outcomes; 2023 Mar; 7(1):22. PubMed ID: 36892714
[TBL] [Abstract][Full Text] [Related]
6. The performance of the EQ-5D-Y-5L compared to the EQ-5D-Y-3L in children and adolescents with cerebral palsy (CP).
Verstraete J; Scott D
Dialogues Health; 2022 Dec; 1():100032. PubMed ID: 38515901
[TBL] [Abstract][Full Text] [Related]
7. The EQ-5D-5L Is Superior to the -3L Version in Measuring Health-related Quality of Life in Patients Awaiting THA or TKA.
Jin X; Al Sayah F; Ohinmaa A; Marshall DA; Smith C; Johnson JA
Clin Orthop Relat Res; 2019 Jul; 477(7):1632-1644. PubMed ID: 30801280
[TBL] [Abstract][Full Text] [Related]
8. Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients.
Pattanaphesaj J; Thavorncharoensap M
Health Qual Life Outcomes; 2015 Feb; 13():14. PubMed ID: 25890017
[TBL] [Abstract][Full Text] [Related]
9. Investigating the psychometric properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, CHU-9D, and PedsQL in children and adolescents with osteogenesis imperfecta.
Xu RH; Zhu L; Sun R; Tan RL; Luo N; Zou S; Dong D
Eur J Pediatr; 2022 Dec; 181(12):4049-4058. PubMed ID: 36156120
[TBL] [Abstract][Full Text] [Related]
10. EQ-5D-Y-3L and EQ-5D-Y-5L proxy report: psychometric performance and agreement with self-report.
Fitriana TS; Purba FD; Stolk E; Busschbach JJV
Health Qual Life Outcomes; 2022 Jun; 20(1):88. PubMed ID: 35659313
[TBL] [Abstract][Full Text] [Related]
11. Testing measurement properties of two EQ-5D youth versions and KIDSCREEN-10 in China.
Pei W; Yue S; Zhi-Hao Y; Ruo-Yu Z; Bin W; Nan L
Eur J Health Econ; 2021 Sep; 22(7):1083-1093. PubMed ID: 33893889
[TBL] [Abstract][Full Text] [Related]
12. Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients.
Fitriana TS; Purba FD; Rahmatika R; Muhaimin R; Sari NM; Bonsel G; Stolk E; Busschbach JJV
Health Qual Life Outcomes; 2021 Nov; 19(1):256. PubMed ID: 34781978
[TBL] [Abstract][Full Text] [Related]
13. Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases.
Scalone L; Ciampichini R; Fagiuoli S; Gardini I; Fusco F; Gaeta L; Del Prete A; Cesana G; Mantovani LG
Qual Life Res; 2013 Sep; 22(7):1707-16. PubMed ID: 23192232
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data.
Bahrampour M; Devlin N; Jones R; Dalziel K; Mulhern B;
Pharmacoeconomics; 2024 Jun; 42(Suppl 1):95-111. PubMed ID: 38748193
[TBL] [Abstract][Full Text] [Related]
15. Psychometric Properties of the Spanish Versions of EQ-5D-Y-3L and EQ-5D-Y-5L in Children with Cancer: A Comparative Study.
Perez-Sousa MA; Olivares PR; Gusi N
Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141694
[TBL] [Abstract][Full Text] [Related]
16. Patient-caregiver agreement and test-retest reliability of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients with haematological malignancies.
Zhou W; Shen A; Yang Z; Wang P; Wu B; Herdman M; Luo N
Eur J Health Econ; 2021 Sep; 22(7):1103-1113. PubMed ID: 33950465
[TBL] [Abstract][Full Text] [Related]
17. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.
Poór AK; Rencz F; Brodszky V; Gulácsi L; Beretzky Z; Hidvégi B; Holló P; Kárpáti S; Péntek M
Qual Life Res; 2017 Dec; 26(12):3409-3419. PubMed ID: 28875430
[TBL] [Abstract][Full Text] [Related]
18. Psychometric performance assessment of Malay and Malaysian English version of EQ-5D-5L in the Malaysian population.
Shafie AA; Vasan Thakumar A; Lim CJ; Luo N
Qual Life Res; 2019 Jan; 28(1):153-162. PubMed ID: 30317426
[TBL] [Abstract][Full Text] [Related]
19. Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds.
van Heusden A; Rivero-Arias O; Herdman M; Hiscock H; Devlin N; Dalziel K;
Pharmacoeconomics; 2024 Jun; 42(Suppl 1):129-145. PubMed ID: 38238604
[TBL] [Abstract][Full Text] [Related]
20. Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression.
O'Loughlin R; Jones R; Chen G; Mulhern B; Hiscock H; Devlin N; Dalziel K;
Pharmacoeconomics; 2024 Jun; 42(Suppl 1):57-77. PubMed ID: 38329689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]